Cell biology and genetics of angiotensin in cardiovascular disease

Journal of Hypertension

Volumn 12, Issue , 1994, Pages S3-S10

  Dzau, Victor J ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin converting enzyme; Cell biology; Genetics; Renin angiotensin

Indexed keywords

ANGIOTENSIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GROWTH FACTOR; GROWTH INHIBITOR; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA1; VASODILATOR AGENT;

ANGIOCARDIOGRAPHY; CARDIOVASCULAR DISEASE; CELL GROWTH; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CYTOLOGY; ECHOCARDIOGRAPHY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENETICS; HEART DEVELOPMENT; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECURRENT DISEASE; VASCULAR LESION;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMAL; BLOOD VESSELS; CARDIOVASCULAR DISEASES; CELL DIVISION; CORONARY DISEASE; HUMAN; VASCULAR DISEASES; VENTRICULAR FUNCTION;

EID: 0028067176     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/00004872-199407030-00002     Document Type: Article

References (66)

1. Dzau VJ, Pratt RE: Renin-angiotensin system. In The Heart and Cardiovascular System. Edited by Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE. New York: Raven Press; 1991:1817-1850.
2. Dzau VJ: Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 1988, 77 (suppl I):I4-I13.
3. Geisterfer AAT, Peach MJ, Owens GK: Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 1988, 62:749-756.
4. Itoh H, Pratt RE, Dzau VJ: Atrial natriuretic factor inhibits hypertrophy of vascular smooth muscle cells. J Clin Invest 1990, 86:1690-1697.
5. Pratt RE, Itoh H, Gibbons GH, Dzau VJ: Role of angiotensin in the control of vascular smooth muscle cell growth. J Vase Med Biol 1991, 3:25-29.
6. Naftilan AJ, Pratt RE, Dzau VJ: Induction of PDGF A-chain and c-myc gene expressions by angiotensin II in cultured vascular smooth cells. J Clin Invest 1989, 83:1419-1424.
7. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ: Multiple autocrine growth factors modulate vascular smooth muscle cell response to angiotensin II. J Clin Invest 1993, 91:2268-2274.
8. Gibbons GH, Pratt RE, Dzau VJ: Vascular smooth muscle cell hypertrophy vs. hyperplasia: autocrine transforming growth factor-pl expression determines growth response to angiotensin II. J Clin Invest 1992, 90:456-461.
9. Dzau MA, Gibbons GH: Endothelium and growth factors in vascular remodeling of hypertension. Hypertension 1991, 18 (suppl II1):III115—III121.
10. Majesky MW, Daeman MJAP, Schwartz SM: Alpha-one adrenergic stimulation of platelet-derived growth factor A- chain gene expression in rat aorta. J Biol Chem 1990, 265:1082-1088.
11. Reidy MA, Fingerle J, Au YO, Majewsky MW: Correlation of mRNA expression of cellular mitogens and smooth muscle cell proliferation in arteries denuded of endothelium [abstract]. J Cell Biochem 1989, 13E (suppl 13):194.
12. Daeman MJAP, Lombardi DM, Bosman FT, Schwartz SM: Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991, 68:450-456.
13. Powell JS, Clozel JP, Miiller RKM, Kuhn H, Hefti F, Hosang M, et al:. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989, 245:186-188.
14. Schwartz SM, Stemerman MB, Benditt EP: The aortic intima: II. Repair of the aortic lining after mechanical denudation. Am J Pathol 1975, 81:15-42.
15. Madri JA, Reidy MA, Kocher O, Bell L: Endothelial cell behavior after denudation injury is modulated by transforming growth factor-p 1 and fibronectin. Lab Invest 1989, 60:755-765.
16. Gibbons GH, Pratt RE, Dzau VJ: Angiotensin is a bifunctional modulator of vascular smooth muscle cell growth: interaction with basic fibroblast growth factor [abstract]. Hypertension 1989, 14:358.
17. Vlodavsky I, Folkmann J, Sullivan R, Fridman R, Ishai- Michaeli R, Sasse J, et al:. Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci USA 1987, 84:2292-2296.
18. Dzau VJ, Gibbons GH, Pratt RE: Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. Hypertension 1991, 18 (suppl II):II100—II105.
19. Araki S, Kawahara Y, Kariya Y, Sunako M, Tsuda T, Fukuzaki H, et al:. Stimulation of platelet-derived growth factor-induced DNA synthesis by angiotensin II in rabbit vascular smooth muscle cell. Biochem Biophvs Res Commtin 1990, 168:350-357.
20. Dzau VJ, Re R: Tissue angiotensin system in cardiovascular medicine: a paradigm shift. Circulation 1994, 89:493-498.
21. Naftilan AJ, Ryan TJ, Pratt RE, Dzau VJ: Localization and differential regulation of angiotensinogen mRNA expression in the vessel wall. J Clin Invest 1991, 87:1300-1311.
22. Louden M, Bing RF, Thurston H, Swales JD: Arterial wall uptake of renal renin and blood pressure control. Hypertension 1983, 5:620-634.
23. Rakugi H, Jacob HJ, Ingelfinger JR, Krieger JE, Dzau VJ, Pratt RE: Angiotensin gene expression in the myointima after vascular injury [abstract]. Hypertension 1990, 16:345.
24. Rakugi H, Kim DK, Krieger JE, Wang DS, Dzau VJ: Induction of angiotensin converting enzyme in the neointima after vascular injury: possible role in restenosis. J Clin Invest 1994, 93:339-346.
25. Lindpaintner K, Ganten D: The cardiac renin-angiotensin system: an appraisal of present experimental and clinical evidence. Circ Res 1991, 68:905-921.
26. Weishaar RE, Panek ILL, Major TC, Simmerman J, Rapundalo ST, Taylor DG: Evidence for a functional tissue renin angiotensin system in the rat mesenteric vasculature and its involvement in regulating blood pressure. J Pharmacol Exp Ther 1991, 256:568-574.
27. Kaplan HR, Taylor DG, Olson SC, Andrews LK: Quinapril: a preclinical review of the pharmacology, pharmacokinetics, and toxicology. Angiology 1989, 40:335-350.
28. Morishita R, Gibbons GH, Ellison KE, Zhang L, Kaneda Y, Ogihara T, et al: Autocrine/paracrine renin angiotensin as a determinant of vascular structure: a gene transfer approach [abstract]. Hypertension 1993, 22:445.
29. MERCATOR Study Group: Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Circulation 1992, 86:100-110.
30. MARCATOR Investigators: Angiotensin converting enzyme inhibition and restenosis: the final results of the MARCATOR Trial [abstract]. Circulation 1992, 86 (suppl I):153.
31. Hanson SR, Powell JS, Dodson T, Lumsden A, Kelly AB, Anderson JS, et al: Effects of angiotensin converting enzyme inhibition with cilazapril on intimal hyperplasia in injured arteries and vascular grafts in the baboon. Hypertension 1991, 8 (suppl II):II70-II76.
32. Vaughan DE, Declerck PJ, Vanhoutte P, De Mol M, Collen D: Reactivated recombinant plasminogen activator inhibitor- 1 (rPAI-1) effectively prevents thrombolysis in vivo. Tbromb Haemost 1992, 68:60-63.
33. Rydzewski B, Zelezna B, Tang W, Sumners C, Raizada MK: Angiotensin II stimulation of plasminogen activator inhibitor- 1 gene expression in astroglial cells from the brain. Endocrinology 1992, 130:1255-1262.
34. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, et al: Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992, 359:641-644.
35. Raynolds MV, Bristow MR, Bush EW, Abraham WT, Lowes BD, Zisman LS, et al: Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet 1993, 342:1073-1075.
36. Marian AJ, Yu QT, Workman R, Greve G, Roberts R: Angiotcnsin-convcrting enzyme polymorphism in hyper trophic cardiomyopathy and sudden cardiac death. Lancet 1993, 342:1085-1086.
37. Ohishi M, Fujii K, Minamino T, Higaki J, Kamitani A, Rakugi H, et al: A potent genetic risk factor for restenosis. Nature Genet 1993, 5:324-325.
38. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH: Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991, 324:1098-1104.
39. Pfeffer M, Braunwald E, Boye L, the SAVE Investigators: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992, 327:669-677.
40. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992, 327:685-691.
41. Chobanian AV: The effects of ACE inhibitors and other anti- hypertensive drugs on cardiovascular risk factors and atherogenesis. Clin Cardiol 1990, 13 (suppl VII):VII43-VII48.
42. Chobanian AV, Haudenschild CC, Nickerson C, Drago R: Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990, 15:327-331.
43. Aberg G, Ferrer P: Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol 1990, 15 (suppl 5):S65-S72.
44. Kidgel RA, Defendini R, Erdos EG: Angiotensin I converting enzyme and its role in neuropeptide metabolism. In Neuropeptides and Their Peptidases. Edited by Turner AJ. New York: Ellis Horwood VCH, 1988:165-168.
45. Carretero OA, Miyazaki S, Scicli AG: Role of kinins in the acute antihypertensive effect of the converting enzyme inhibitor, captopril. Hypertension 1981, 3:18-22.
46. Garg UC, Hassid A: Nitric oxide generating vasodilators and 8-bromo cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989, 83:1774-1777.
47. Radomski MW, Palmer RMJ, Moncada S: An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 1990, 87:5193-5197.
48. Kubes P, Suzuki M, Granger DN: Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991, 88:4651-4655.
49. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME: Antiatherogenic effects of L-arginine in the hypercholes- terolemic rabbit. J Clin Invest 1992, 90:1168-1172.
50. Becker RHA, Weimer G, Linz W: Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet. J Cardiovasc Pharmacol 1991, 18 (suppl 2):S110-S115.
51. Webb RC, Finta KM, Fisher M, Lee L, Pitt B: Ramipril reverses impaired endothelium-dependent relaxation in arteries from rabbits fed an atherogenic diet [abstract]. FASEB J 1992, 6:A1458.
52. Jayakody L, Kappagoda T, Senaratne MPJ, Thomson ABR: Impairment of endothelium-dependent relaxation: an early marker for atherosclerosis in the rabbit. Br J Pharmacol 1988, 94:335-346.
53. Ragazzi E, Froldi G, Pandolfo L, Chinellato A, De Biasi M, Prosdocimi M, el al.: Segmental impairment of endothelium- mediated relaxation in thoracic aortas from atherosclerotic rabbits: comparison to cholesterol infiltration and energy metabolism. Artery 1989, 16:327-345.
54. Farhy RD, Carretero OA, Ho KL, Scicli AG: Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ Res 1993, 72:1202-1210.
55. Dzau VJ, Colucci WS, Hollenberg NK, Williams GH: Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981, 63:645-651.
56. Dargie HJ, McAlpine HM, Morton JJ: Neuroendocrine activation in acute myocardial infarction. J Cardiovasc Pharmacol 1987, 9 (suppl 2):S21-S24.
57. Hirsch AT, Cant JR, Dzau VJ, Batger AC: Sequential cardiorenal responses to rapid ventricular pacing in the conscious dog [abstract]. FASEB J 1988, 2:A829.
58. Hodsman GP, Kohzuki M, Howes LG, Sumithran E, Tsunoda K, Johnston CI: Neurohormonal responses to chronic myocardial infarction in rats. Circulation 1988, 78:376-381.
59. Hirsch AT, Talsnes CE, Schunkert H, Paul M, Dzau VJ: Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res 1991, 69:475-482.
60. Dzau VJ: Tissue renin angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993, 153:937-942.
61. Hirsch AT, Dzau VJ: Tissue renin angiotensin systems: insights regarding the pathophysiology of heart failure. Heart Failure 1991, 7:59-70.
62. Jackson B, Mendelsohn FAO, Johnston CI: Angiotensin-converting enzyme inhibition: prospects for the future. J Cardiovasc Pharmacol 1991, 18 (suppl 7):S4-S8.
63. Lees RS, Dinsmore RE: Can ACE inhibition alter the course of coronary heart disease? Rationale and protocol for QUIET. J Cardiovasc Pharmacol 1992, 20 (suppl B):S33-S35.
64. Texter M, Lees RS, Pitt B, Dinsmore RE, Uprichard ACG: The QUinapril Ischemic Event Trial (QUIET) design and methods: evaluation of chronic ACE inhibitor therapy after coronary artery intervention. Cardiovasc Drugs Ther 1993, 7:273-282.
65. Fabris B, Chen B, Pupic V, Perich R, Johnston CI: Inhibition of angiotensinconverting enzyme (ACE) in plasma and tissue. J Cardiovasc Pharmacol 1990, 15 (suppl 2):S6-S13.
66. Johnston CI, Fabris B, Yamada H, Mendelsohn FAO, Cubela R, Sivell D, et al.: Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertens 1989, 7 (suppl 5):S11-S16.